The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)

Autor: Deau, Bénédicte, Nicolini, Franck E., Guilhot, Joelle, Huguet, Françoise, Guerci, Agnès, Legros, Laurence, Pautas, Cécile, Berthou, Christian, Guyotat, Denis, Cony-Makhoul, Pascale, Gardembas, Martine, Michallet, Mauricette, Hayette, Sandrine, Cayuela, Jean Michel, Weiss, Isabelle Radford, Réa, Delphine, Castaigne, Sylvie, Mahon, François-Xavier, Guilhot, François, Rousselot, Philippe
Zdroj: In Leukemia Research June 2011 35(6):777-782
Databáze: ScienceDirect
Externí odkaz: